And the 2026 PRIME winners are...
Three companies were the biggest winners at last night's PRIME awards ceremony, each celebrating three wins. Find out who took home a gong...
Three companies were the biggest winners at last night's PRIME awards ceremony, each celebrating three wins. Find out who took home a gong...
The company's biggest competitor will not be "Lilly or AstraZeneca" but a far fiercer rival, the CEO says, and all Big Pharmas will have to lift their game
Industry body says reports the Federal Government might freeze the PBS co-pay carries little weight if the drugs patients need don't come to Australia
The neck-and-neck battle to be the first to the Australia market with an oral GLP-1 drug for weight loss has hit fever pitch with Novo unveiling a launch date
Funding boost to support the development of a gene therapy candidate for a devastating neurodegenerative disease
The PBAC will consider 19 changes to listings next March, including some big new indications and another multi-cancer reimbursement submission
On the super-sized list for the March 2027 meeting are 13 drugs and two vaccines vying to secure a recommendation to win government subsidy for the first time
Two weeks after Novo's obesity pill won TGA approval, Lilly seems to have stolen first-to-market advantage after securing registration for its rival treatment yesterday, promising to launch in "days"
Australia has the smarts to become a regional leader in the cell & gene therapy space, but a dismal patient access record is thwarting the industry's ambition
A new tool gives pharma visibility across the entire digital information ecosystem, detailing what doctors and patients are privately asking about a company's drugs - and their competitor's - as well as what they're being told
$5B acquisition puts J&J head-to-head with both Bayer and Roche with a "potentially transformative" drug that could redefine patient care
There have been changes to the Top 10 PBS Drugs List with a couple of treatments taking a tumble while most others have soared
As 2026 hurtles to the finish line, companies are filling slots ahead of the end of year break with more job changes across industry
New membership marks yet another sign that this pharma is quickly cementing itself in Australia's biopharmaceutical industry
The drugs work and get ticks overseas, but Australia's inflexible reimbursement system means three medicines addressing unmet need, were knocked back
The FDA has declined to approve Summit's highly-anticipated challenger to the world's biggest drug, but analysts are branding the decision "very much a one-off"
Mayne Pharma is on the block again, with a new suitor eager to buy the company in a deal worth more than $600M but without its Australian business
Roundtable convened to put the pedal to the metal in moving rare cancer therapies through the HTA processes.
One of the most age diverse workforces in history is seeing Boomers, Gen X, Millennials and Gen Z working side-by-side but communication style is one of the biggest sticking points
Twelve pharmas are jostline to score the last PBS listings for the year, from brand new drugs to new indications, with two companies vying to win two additions
After opening its Australian operations in 2001 with just four full-time employees, this pharma now has a 67-strong workforce
A monster return after just five weeks on the market has led one analyst to dub the launch of this cancer drug, the GOAT
The TGA has approved a new treatment for contraception and endometriosis plus a new contrast agent for enhanced diagnostic imaging
Recently recertified as a Kind Company this company reveals how its ANZ team is embedding kindness into its everyday culture and beyond
This pharma has picked up the prestigious Most Preferred Supplier gong at the Self-Care Excellence Awards but another company scored the highest number of recognitions, with four wins
Shortages of some hormone replacement therapy patches are expected to continue well into 2027 after sponsors provided the TGA with an updated outlook for supply
Ending a rival's two-year reign, this pharma has snatched the lead in digital innovation, praised for making AI an 'enterprise backbone'
The regulator has raised fresh concerns about fakes of Lilly's experimental weight loss drug, homing in on a specific branded counterfeit
LifeSciences Australia went from wallowing in dire straits three years ago to clear sailing now, earning it a prestigious recognition for its stellar turnaround
For the 18th year running Vertex has undertaken its Global Week of Service with the Aussie team pitching in on a home improvement project